Odyssey Therapeutics, Inc.
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $775.1M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $775.1M
- Shares outstanding
- 45.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 8, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Odyssey Therapeutics, Inc..
